#202 Dementia Part 2: Gray Matters Segment
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
#202 Dementia Part 2: Gray Matters Segment
-
ナレーター：
-
著者：
概要
Most clinicians see dementia medications on the med rec, but many of us aren’t sure how much they actually help. In this episode we break down donepezil, memantine, and the new anti-amyloid drugs, and when to stop them.
• Do cholinesterase inhibitors really work?
• What should clinicians know about lecanemab and donanemab before referring patients?
• How much benefit should we expect and for how long?
• When should you deprescribe dementia medications?
🔹Sponsor: Caraway’s cookware set is a favorite for a reason.
For 10% off, go to Carawayhome.com/CoreIM or use code CoreIM at checkout.
🔹Transcript and Shownotes
02:27 | Deep Dive 1: How do we deliver the news of a diagnosis of dementia?
09:41 | Deep Dive 2: Prescribing medications for cognitive decline
29:30 | Deep Dive 3: Patient-centered management for a patient with cognitive decline
35:46 | Deep Dive 4: Planning for an uncertain future
Tags: CoreIM, Internal Medicine, Medical Education, Cognitive Screening, primary care, nurse practitioner, physician assistant
Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy